Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs
Source: SeekingAlpha
2025-12-26 10:41:52 ET
More on Organogenesis Holdings, MiMedx Group
- Organogenesis: High-Tech Skin Substitute Company On Sale
- Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
- MiMedx: Breakout Setup Into A Policy Overhaul
- Organogenesis starts rolling submission for ReNu allograft for knee arthritis
- Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook
Read the full article on Seeking Alpha
For further details see:
Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs
Organogenesis Holdings Inc.
NASDAQ: ORGO
ORGO Trading
1.96% G/L:
$2.7324 Last:
171,756 Volume:
$2.80 Open:
ORGO Latest News
February 26, 2026 04:05:00 pm
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
February 19, 2026 04:05:00 pm
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
ORGO Stock Data
$490,515,429
46,830,580
2.02%
145
N/A
Pharmaceuticals
Healthcare
US
Canton
